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Summary Fifteen human glioma cell lines were examined for their sensitivity to 1 ,3-bis(chloroethyl)-nitrosourea (BCNU, carmustine) and cis-
dichlorodiamminoplatinum (cisplatin), the induction of DNA interstrand cross-linking (DNA-ISC) induced by the two agents and cellular 06_
alkylguanine alkyltransferase (ATase) activity. Cell lines differed in their sensitivities to BCNU by up to 12-fold and to cisplatin by up to 21-fold.
For both drugs, the extent of DNA-ISC was related to the drug sensitivity. There was a wide range of cellular ATase levels. Increasing ATase
levels correlated with increased resistance to BCNU and with decreased formation of DNA-ISC following treatment with BCNU. In contrast,
following treatment with cisplatin, there was no correlation between cellular ATase content and cytotoxicity or between ATase and DNA-ISC.
Four sublines of varying ATase activity were prepared from one of the cell lines. These sublines showed a sensitivity to BCNU in inverse
proportion to ATase activity, while sensitivity to cisplatin was more uniform. The experiments confirm the direct relationship between ATase
concentration and sensitivity to BCNU in glioma cells. Although there was some correlation between cisplatin cytotoxicity and BCNU
cytotoxicity, this was not mediated through ATase.
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The treatment for high-grade gliomas remains relatively ineffec-
tive. Chloroethylnitrosoureas (CNUs) are among the most effec-
tive cytotoxic agents used, but only 30% of tumours show a
response, and this is usually short lived (Fine et al, 1993). It has
generally been accepted that the formation of cross-links between
complementary strands of duplex DNA represents the crucial
mechanism for the cytotoxic, anti-tumour activity of CNUs. The
exact details of the mechanism of cross-link formation are not
entirely clear. Initial evidence suggested that the DNA-ISC was
produced via an initial alkylation at the guanine 06 position
followed by a link to a cytosine on the opposite strand (Kohn,
1977; Erickson et al, 1980; Tong et al; 1982) because cell lines
defective in repair of 06-methylguanine were hypersensitive to
both the cytotoxic and the DNA cross-linking effects of CNUs.
However, the only di-adduct identified that might represent the
cross-link structure in CNU-treated duplex DNA did not involve
the 06 position of guanine. It was then proposed that an initial
alkylation by a chloroethyl ion at 06-guanine is followed by
intramolecular rearrangement via 06, N'-ethanoguanine to yield
the observed N3-cytosine, N'-guanine ethane cross-link (Tong et
al, 1982; Gonzaga et al, 1989). It is generally accepted that ATase,
a DNA repair protein, causes resistance to CNUs by removing the
chloroethyl groups from the guanine 06 position and preventing
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the formation of the DNA-ISC (Robins et al, 1983; Brent, 1984).
Cell lines resistant to CNUs generally have a low level of DNA-
ISCs and a high level of ATase. In contrast, cisplatin, which also
shows activity in glioma treatment, causes intrastrand cross-links
and DNA-ISC through guanine N7 positions, and these lesions are
not repaired by ATase (Lippert, 1981; Eastman, 1982). Previous
studies of the mechanism ofcytotoxicity ofcisplatin and CNUs in
a variety of human and rodent cell lines have given conflicting
results, with some showing correlation between DNA-ISC produc-
tion by both CNUs and cisplatin (Sariban et al, 1987) and others
showing no correlation between either cytotoxicity or DNA-ISC
induced by the two agents (Laurent et al, 1981; Bodell et al, 1985;
Aida et al, 1987). A correlation between the two drugs may be
related to DNA repair mechanisms other than ATase. The relation-
ship between ATase, CNU cytotoxicity and DNA damage induced
by CNUs has not been assessed in human glioma cell lines and
compared directly with the action of a cytotoxic agent in which
repair of the DNA-drug adduct is not mediated by ATase. There
therefore remains some uncertainty about the degree to which
ATase activity is responsible for sensitivity of glioma cells to
CNUs. The current study was undertaken to further define this
relationship.
MATERIALS AND METHODS
Cell cultures were established from biopsy specimens of grade III
and IV gliomas. One line was multiply passaged (passages
569-576) and 14 were early passage (passages 4-20). Four addi-
tional cell lines were prepared from a single line (SB) by plating
one cell per well in a 96-well plate. Twenty cell lines were cultured
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Table 1 Cytotoxicity and DNA crosslinking by BCNU and cisplatin and ATase levels in 15 human glioma cell lines. Cytotoxicity (IC50) was measured using the
sulphorhodamine B assay, and Crosslink Index (CLI) was assessed by alkaline elution
Cell line BCNU Cisplatin
ATasea IC5(0M) CLI(50 gM) CLI (100gM) IC1SO(gM) CLI (10(gM) CLI (20 gM)
1265 0 30.2±4.5 63.1±11 123.3b 31.7±7.6 55.3b 80.3±14.6
859 0 29.8±4.5 57b 96.7±16.5 27.5±8.6 37.4b 129.1b
1724 0 30±6.1 63.3b 125.3b 30.7±5.1 65.3b 241 b
1612 0 23.3±6 114c 175c 13.8±3.9 93c 224.7c
478 20.7+24 171.7±7.6 145.6±9b 197.5b 70b 174.5b 446c
118 24.8±2.2 70.3±7.4 48.6±4.4 90.8±2.5 21.7±5.8 99±16.1 246±56
1854 90±23 152±25 16.6b 49.6b 151.3±25 69.4b 269.1b
1675 90.8±43 160c 17c 35c 183±30.6 46c 142c
1468 97.5b 130c 25c 81c 300c 7c 35c
1461 97b 155b 35.5c 65c 165c 52c 114c
1800 103b 101.7c 78c 77c 172c
1708 i1Ob 137.5b 13c 30c 287.5b 23c 43c
1407 119c 170c 3c 31c 200c 17c 35c
1610 137c 165b 18c 30c 135c 33b 69b
SB 211.7±28 190±36 18.8±9.7 31.7±5.8 24.8±7.6 220.6±45 477+201
aATase was determined as described in 'Materials and methods'. Values are expressed as fmol mg-1 protein. bTwo independent experimental estimations. cOne
experimental estimate.
and four sublines, with varying ATase activity (0-155 fmol mg-'
protein) were selected for further assessment. Cell lines were
maintained in Ham's FlO medium (Gibco) with 10% fetal calf
serum (Gibco). BCNU was dissolved in dimethylsulphoxide
(DMSO) and medium without fetal calf serum, with the final
concentration of DMSO being less than 0.5%. Cisplatin was
dissolved in media without fetal calf serum and incubated at 37°C
for 30 min before use. Control cells were incubated in the drug
vehicle. All drugs were reconstituted immediately before treat-
ment. As cell numbers were restricted in low passage lines, it was
only possible to analyse some cell lines on one occasion in the
chemosensitivity assay, alkaline elution and ATase assay.
Cytotoxicity assay
Drug-induced cytotoxicity was analysed using the sulphorho-
damine B assay (SRB) (Rubinstein et al, 1990). Cells were plated
at a density of 0.5-1.0 x 104 cells per well in 96-well plates and
were allowed to grow for 24 h before the addition of drug. The
drug was removed at 2 h andreplaced with fresh medium, and the
cells were allowed to grow for 4-6 days. The cells were then
treated with 10% trichloroacetic acid for 30 min, washed five
times with water, stained with 0.4% SRB in 1% acetic acid for 15
min and washed five times with 1% acetic acid. After air drying
overnight, the SRB was solulibized with 100 ,l of 10 mm Tris
base, and the plates were read at 540 nm. The IC50 (concentration
ofdrug required to cause 50% growth inhibition ofcells) ofdrug
values was calculated from treated and control cells.
Alkaline elution
Cells (0.25-0.5 x 106) wereplated into 25-cm2 flasks and allowed to
settle before adding labelled medium (0.015 gCi ml ['4C]thymi-
dine, specific activity 52 mCi ml-1) and were grown for 1-3 days.
Excessradioactivity was removedbywashing, andthe cultures were
grown for an additional 12-24 h to allow for the incorporation of
labelled DNA intohigh molecularweight DNA. Cells wereexposed
to drug for 2 h and then washed with fresh medium. The cells were
incubated in the absence ofdrug for6 h to allow forthe formation of
DNA-ISC. The cells were irradiated at 0°C with 4.5 gray (Gy) at a
dose rate of 4.5 Gy min-'. The elution procedure used was essen-
tially that described previously by Kohn (1981). The cross-link
index (CLI) was calculated after 12 h elution using the formula
CLI=(Il-RO)/(1-R )-1
whereRo and R1 are the relative retention for untreated and treated
cells respectively (Ewig et al, 1978). Some cell lines had a signifi-
cant number of drug-induced single-strand breaks and therefore
newR, values were corrected (Kohn, 1981).
ATase assay
Cell extract was prepared by suspending a cell pellet (10 x 107
cells) in 2 ml of buffer I (50 mM Tris, 1 mM DTT, 1 mM EDTA).
This was sonicated on ice and then centrifuged at 10000 r.p.m. for
10 min. The supematant was collected and the protein concentra-
tion in the supematant was determined. Cell extract was mixed for
2 h with [3H]methylated DNA substrate (0.1 mg ml-'; specific
activity 23 Ci mmol-') kindly supplied by Dr G Margison
(Paterson Institute for Cancer Research, Manchester UK). The
reaction was stopped by 4 Mperchloric acid and 10 mg ml-'bovine
serum albumin, and the remaining radioactive labelled DNA was
hydrolysed by heating at 75°C for 45 min. The precipitate was
dissolved in 10 mm sodium hydroxide, and incorporated radioac-
tivity was counted.
Statistical analysis
Statistical tests were carried outusing the SPSS statistical software
(SPSS, Chicago, IL, USA). Tests for association between pairs of
variables were based on Pearson correlation coefficents. Tests for
dependence of a variable on two independent variables were made
by multiple linear regression analysis. Results were regarded as
statistically significant at P<0.05.
British Journal ofCancer(1997) 75(4), 500-505 0 Cancer Research Campaign 1997502 J Beith etal
A
0 50 100 150 200
ATase (fmol-1 mg protein)
15(
x
Co
Co
0
104
54
250 0 50 100 150 200 250
ATase (fmol-1 mg protein)
Figure 1 Relationship between ATase level and (A) IC50 of BCNU and (B) cross-link index at 100 gm BCNU. Thirteen of the 15 cell lines were early passage
and, because of the large cell numbers required, some estimations were single or in duplicate as cell numbers were restricted at low passage numbers
RESULTS
Figure 2 Correlations between ATase level and IC50 values and crosslinking
indices for BCNU and cisplatin. The thickness of the bars represents the
level of significance and numbers are P-values. Statistical significant
(P<0.05) values are shown with solid bars
ATase levels were measured in 15 human glioma cell lines, their
sensitivity to BCNU and cisplatin assessed and their relative DNA-
ISC indices measured following treatment with the two agents. The
results are shown in Table 1, ranking the cell lines in order of
increasing ATase. The glioma cell lines varied greatly in the ATase
level from 0 to 212 fmol mg-1 protein. Figure 1 shows the relation-
ship between ATase activity and (A) IC50 of BCNU and (B) cross-
link index. The correlation coefficient between ATase and BCNU
cytotoxicity was significant (P<0.001), higher levels ofATase (over
90 fmol mg-' protein) being associated with IC50 values over five
times as high as those in cell lines with undetectable ATase levels.
There was also a strong correlation (P<0.001) between ATase and
BCNU-induced cross-linking. The correlation coefficients for all
the parameters are shown in Figure 2. There was no significant
correlation (P=0.093) between cisplatin cytotoxicity and ATase
activity or between cross-linking by cisplatin and ATase (P=0.9).
Both drugs, however, showed a relationship between IC50 and
cross-linking (P<0.05). Cell lines having high levels ofATase were
thus resistant to BCNU and had few DNA interstrand cross-links.
One cell line (478) did not conform to this distribution with an
ATase of 21 fmol mg-' protein and a high level of DNA-ISC
but was relatively resistant to the cytotoxic effect of BCNU.
Finally, a weaker association ofcellular resistance (IC50 value) was
observed between the two drugs (P<0.05) by comparing IC50
values. Figure 2 relates to tests for the pairwise association ofvari-
ables. In addition to these, multiple linear regression analysis was
used in an attempt to find dependencies of each ofthe variables on
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Figure 3 Relationship in sublines between ATase level (a-0, b-53, c-146, d-155 fmol mg-' protein) and (A) IC50 of BCNU, (B) IC50 of cisplatin, (C) cross-link
index at 50 lIM BCNU and (D) cross-link index at 20 gM cisplatin
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combinations of the other variables, however no consistent pattern
could be discerned.
Sublines were derived from line SB, which varied in ATase from
0 to 155 fmol mg-' protein. There was a clearrelationship between
increased ATase level and increased resistance (Figure 3A) and
decreasing DNA-ISC (Figure 3C), following treatment with
BCNU. In contrast, the sublines all remained relatively sensitive to
treatment with cisplatin (Figure 3B), and all had a high level of
DNA-ISC (Figure 3D).
DISCUSSION
These results confirm that ATase levels vary in human glioma cell
lines and that a high level of ATase correlates with resistance and
decreased DNA-ISC formation in cell lines after treatment with
BCNU. They also show a weak correlation between cellular resis-
tance to BCNU andcisplatin.
Cell lines with ATase level greater than 25 fmol mg-' protein
were more resistant to BCNU and had fewer DNA interstrand
crosslinks induced by this agent. Once the level of ATase was
greater than 90 fmol mg-' protein, the cell lines were generally
very resistant and any increase in ATase above 90 fmol mg-'
protein did not significantly increase resistance or decrease the
number of DNA cross-links to BCNU. This suggests that there is a
plateau level of ATase protection against DNA damage by CNUs,
and above that level other mechanisms may be important. These
results confirm previous studies (Aida et al, 1987; Sariban et al,
1987) that concluded that ATase is an important mechanism of
resistance to CNUs in glioma lines and that high levels of ATase
are associated with fewer DNA interstrand cross-links. Similar
results have been reported from cell lines from a variety ofmalig-
nant tumours (Robins et al, 1983; Brent, 1984; Bodell et al, 1986;
Ludlum et al, 1986).
One cell line (478) did not conform to this distribution, and
there is no explanation for this observation. This cell line also had
a level of DNA-ISC induced by cisplatin out of proportion to its
sensitivity and thus may lack a different DNA repair mechanism,
thereby possessing an alternative mechanism ofdrug resistance.
This study has more precisely established the relationship of
ATase level to CNU and another DNA-binding drug, cisplatin.
There was no significant correlation observed for ATase in relation
to cytotoxicity or DNA-interstrand cross-links induced by
cisplatin; this was notexpected ascisplatin forms DNA interstrand
cross-links through the N7 position of guanine (Eastman, 1982).
There was, however, a correlation between sensitivities to BCNU
and cisplatin, which implies that there may be an additional and
associated mechanism of resistance. The results in the sublines of
the cell line SB would suggest that this was not mediated through
ATase as they showed excellent correlation between increasing
ATase andincreasing resistance and DNA-ISC after treatment with
BCNU but showed little variation in resistance or DNA-ISC
induced after treatment with cisplatin. Interestingly, however, the
SB line, in contrast to the trend with other cell lines with high
ATase, was very sensitive to cisplatin and had a corresponding
high level of DNA-ISC induced by this agent. If this cell line is
omitted from the statistical analysis the IC50 for cisplatin becomes
strongly correlated with ATase (P < 0.01) in the other 14 lines.
Other investigators have not simultaneously correlated DNA-
ISC, cytotoxicity and ATase in cisplatin- and CNU-treated cells.
One report examined 13 human glioma cell strains and found that
there was a weak but significant correlation between DNA-ISC
induced by cisplatin and BCNU. Two of the cell lines were
assessed for sensitivity to BCNU, which showed that the MER +ve
cell line was more resistant to CNU than the MER -ve cell line. No
cell lines were examined for sensitivity to any other alkylating
agent (Sariban et al, 1987). In contrast, another study examined
five well-established human glioma cell lines and also found high
ATase levels correlated with resistance and decreased DNA-ISC to
CNU, but, in cell lines with intermediate resistance or sensitivity,
the level of DNA-ISC was the same. They concluded that there
was no correlation between CNU and cisplatin in cell kill, number
of sister chromatid exchanges induced and degree of DNA-ISC.
Closer examination ofthese results shows that all the cell lines had
a similar number of cross-links formed after treatment with
BCNU, except for the one line that was resistant, which had fewer
crosslinks. All the cell lines had a similar cytotoxicity, DNA-ISC
and sister chromatid exchanges after treatment withcisplatin (Aida
et al, 1987). A further series examined ten different human cell
lines and found no statistically significant correlation between
cytotoxicity tocisplatin or DNA-ISC induced by cisplatin and Mer
phenotype. There appeared to be a trend towards Mer +ve cell
lines being more resistant to cisplatin. These results are similar to
our findings, but cytotoxicity to cisplatin was not correlated with
cytotoxicity to a nitrosourea (Laurent et al, 1981). Another study
investigated four rat brain tumour cell lines and found that resis-
tance to BCNU was associated with decreased cross-link forma-
tion. In these cell lines, cytotoxicity and the number of DNA
cross-links formed after treatment with cisplatin were similar. The
cell lines used in this experiment were cultured after exposure to
CNUs and thus may have selected out cells with resistant mecha-
nisms specific for CNUs, similar to the sublines in our study
(Bodell et al, 1985). Indirect evidence that showed that N-methyl-
N'-nitro-N-nitrosoguanidine pretreatment before cisplatin did not
increase cytotoxicity or DNA-ISC led the authors to conclude that
there was no cross-resistance between CNUs and cisplatin; how-
ever, they did not compare the relative sensitivities and ability to
induce DNA-ISC ofthe two agents (Gibson etal, 1985). In support
of our study, it has been shown that novobicin pretreatment to
inhibit topoisomerase II activity has decreased the rate ofrepair of
both cisplatin- and BCNU-induced DNA interstrand cross-links,
with a corresponding increase in cytotoxicity. This implies that a
DNA repair mechanism is involved in resistance to both these
agents (Ali-Osman et al, 1993). More recently, a report ofprelimi-
nary data showing response to cisplatin and cyclophosphamide in
patients with ovarian carcinoma showed correlation with a low
ATase level (Chen et al, 1994). This association, together with our
results, suggests that there may be an additional resistance mecha-
nism associated with ATase expression which confers resistance to
cisplatin.
Although the relationship between resistance to BCNU and
cellular activity of ATase has been shown previously, there was
still uncertainty as to how important ATase is as a mechanism of
resistance. This study indicates that ATase is the major mechanism
of resistance to BCNU in glioma cells. It has also demonstrated
cross-resistance between BCNU and cisplatin that is not related to
ATase, implying that there may be an additional and associated
mechanism ofresistance.
ACKNOWLEDGEMENTS
This project was supported by the Cancer Research Campaign
(Grant SP1552/0701). JB acknowledges the Cancer Research
British Journal of Cancer(1997) 75(4), 500-505 0 CancerResearch Campaign 1997ATase, DNA-ISC and cytotoxicity induced by BCNU and cisplatin 505
Campaign for a Clinical Research Training Fellowship in Medical
Oncology. Paul Nicholson is thanked for the statistical analysis.
REFERENCES
Aida T and Bodell WJ (1987) Cellular resistance to chloroethylnitrosoureas,
nitrogen mustard, and cis-diamminedichloroplatinum (II) in human glial-
derived cell lines. Cancer Res 47:1361-1366
Ali-Osman F, Berger MS, Rajagopal S, Spence A and Livingston RB (1993)
Topoismerase 11 inhibition and altered kinetics of formation and repair of
nitrosourea and cisplatin-induced DNA interstrand cross-links and cytotoxicity
in human glioblastoma cells. Cancer Res 53: 5663-5668
Bodell WJ, Gerosa M, Aida T, Berger MS and Rosenblum ML (1985) Investigation
of resistance to DNA crosslinking agents in 9L cell lines with different
sensitivities to chloroethylnitrosoureas. Cancer Res 45:3460-3464
Bodell WJ, Aida T, Berger MS and Rosenblum ML (1986) Increased repair of
06-alkylguanine DNA adducts in glioma-derived human cells resistant to the
cytotoxic and cytogenetic affects of 1,3-bis(2-chloroethyl)-I-nitrosourea.
Carciniogeniesis 7:879-883
Brent TP (1984) Suppression ofcross-link formation in chloroethylnitrosourea-
treated DNA by an activity in extracts ofhuman leukemic lymphoblasts.
Cancer Res 44:1887-1892
Chen SS, Citron MC, Spiegel G and Yarosh D (1994) 06-methylguanine-DNA
methyltransferase in ovarian malignancy and its correlation with postoperative
response to chemotherapy. Gvnecol Oncol 52: 175-179
Eastman A (1982) Separation and characterization ofproducts resulting from the
reaction ofcis-diamminedichloroplatinum (11) with deoxyribonucleosides.
Biochemistry 21: 6732-6736
Erickson LC, Laurent G, Sharkey NA, and Kohn KW (1980) DNA crosslinking and
monoadduct repair in nitrosourea-treated human tumour cells. Nature 228:
727-729
Ewig RAG and Kohn KW (1978) DNA protein crosslinking and DNA interstrand
crosslinking by haloethylnitrosoureas in L1210 cells. CatncerRes 38:
3197-3203
Fine HA, Dear KBG, Loeffler JS, Black PM and Canellos GP (1993) Meta-analysis
of radiation therapy with and without adjuvant chemotherapy for malignant
gliomas in adults. Cancer 71: 2585-2597
Gibson NW, Zlotogorski C and Erickson LC (1985) Specific DNA repair
mechanisms may protect some human tumor cells from DNA interstrand
crosslinking by chloroethylnitrosoureas but not from crosslinking by other anti-
tumor alkylating agents. Carcinogenesis 6: 445-450
Gonzaga PE and Brent TP (1989) Affinity purification and characterization of
human 06-alkylguanine-DNA alkyltransferase complexed with BCNU-treated,
synthetic oligonucleotide. Nucleic Acids Res 17: 6581-6590
Kohn KW (1977) Interstrand crosslinking of DNA by 1,3-bis(2-chloroethyl)-I -
nitrosourea and other 1-(2-haloethyl)- -nitrosoureas Cancer Res 37:
1450-1454
Kohn KW (1981) Measurements of strand breaks and cross-links by alkaline elution.
ln DNA Repair A LaboratoryManual ofResearch Procedures, Vol. 1, Part B,
Friedberg EC and Hanawalt PC (eds), pp. 379-401. Marcel Dekker:
New York
Laurent G, Erickson LC, Sharkey NA and Kohn KW (1981) DNA cross-linking and
cytotoxicity induced by cis-diamminadichloroplatinum(lI) in human normal
and tumour cell lines. Cancer Res 41: 3347-3351
Lippert B (1981) Effects on N7 platinum binding on the hydrogen- bonding behavior
of9-ethylguanine. JAmer Chem Soc 103: 5691
Ludlum DB, Mehta JR and Tong WP (1986) Prevention of 1-(3- deoxycytidyl),
2-( I-deoxyguanosinyl)ethane cross-link formation in DNA by rat liver
06-alkylguanine-DNA alkyltransferase. Cancer Res 46: 3353-3357
Robins P, Harris A, Goldsmith I and Lindahl T (1983) Cross-linking of DNA
induced by chloroethyl-nitrosourea is prevented by 06-methylguanine-DNA
methyltransferase. NucleicAcids Res 11: 7743-7758
Rubinstein LV, Shoemaker RH, Paull KD, Simon RM, Tosini S, Skelan P,
Scudiero DA, Monks A and Boyd MR (1990) Comparison of in vitro
anticancer-drug-screening data generated with a tetrazolium assay versus a
protein assay against a diverse panel of human tumour cell lines. J Natl Cancer
Inst 82: 1113-1118
Sariban E, Kohn KW, Zlotogorski C, Laurent G, D'Incalci M, Day R, Smith BH,
Komblith PL and Erikson LC (1987) DNA cross-linking responses ofhuman
malignant glioma cell strains to chloroethylnitrosoureas, cisplatin, and
diaziquone. Cancer Res 47: 3988-3994
Tong WP, Kirk MC and Ludlum DB (1982) Formation ofthe cross-link I[N(3)-
deoxycytidyl], 2-[N(l)-deoxyguanosinyl]ethane in DNA treated with N,N-
bis(chloroethyl)-N-nitrosourea. Cancer Res 42: 3102-3105
C Cancer Research Campaign 1997 British Journal ofCancer(1997) 75(4), 500-505